MA47215A - Procédés prédictifs et diagnostiques pour le cancer de la prostate - Google Patents

Procédés prédictifs et diagnostiques pour le cancer de la prostate

Info

Publication number
MA47215A
MA47215A MA047215A MA47215A MA47215A MA 47215 A MA47215 A MA 47215A MA 047215 A MA047215 A MA 047215A MA 47215 A MA47215 A MA 47215A MA 47215 A MA47215 A MA 47215A
Authority
MA
Morocco
Prior art keywords
predictive
prostate cancer
diagnostic procedures
diagnostic
procedures
Prior art date
Application number
MA047215A
Other languages
English (en)
Inventor
Krishnan Nandabalan
Luca Rastelli
Original Assignee
Bioxcel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxcel Therapeutics Inc filed Critical Bioxcel Therapeutics Inc
Publication of MA47215A publication Critical patent/MA47215A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MA047215A 2017-01-09 2018-01-09 Procédés prédictifs et diagnostiques pour le cancer de la prostate MA47215A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762443831P 2017-01-09 2017-01-09
US201762473507P 2017-03-20 2017-03-20
US201762561218P 2017-09-21 2017-09-21

Publications (1)

Publication Number Publication Date
MA47215A true MA47215A (fr) 2019-11-13

Family

ID=62791142

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047215A MA47215A (fr) 2017-01-09 2018-01-09 Procédés prédictifs et diagnostiques pour le cancer de la prostate

Country Status (5)

Country Link
US (2) US11613785B2 (fr)
EP (1) EP3565560B1 (fr)
ES (1) ES2988845T3 (fr)
MA (1) MA47215A (fr)
WO (1) WO2018129497A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116059219A (zh) 2015-07-16 2023-05-05 比奥克斯塞尔医疗股份有限公司 一种使用免疫调节治疗癌症的新颖方法
US11613785B2 (en) 2017-01-09 2023-03-28 Onkosxcel Therapeutics, Llc Predictive and diagnostic methods for prostate cancer
US20220089733A1 (en) * 2018-12-10 2022-03-24 Bioxcel Therapeutics, Inc. Novel approach for treatment of cancer using immunomodulation
EP3893888A4 (fr) * 2018-12-10 2022-08-31 Bioxcel Therapeutics, Inc. Traitements combinés pour traiter des maladies à l'aide d'un agent modifiant l'immunité innée et d'un agoniste de l'ox40
KR20230125672A (ko) * 2022-02-21 2023-08-29 사회복지법인 삼성생명공익재단 암 환자에 대한 면역관문억제제의 반응성 예측용 조성물
WO2024097856A1 (fr) * 2022-11-03 2024-05-10 Onkosxcel Therapeutics, Llc Biomarqueurs prédictifs pour la réactivité à des inhibiteurs de dpp dans des cancers

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
EP1498427B1 (fr) 1992-08-21 2009-12-16 Vrije Universiteit Brussel Immunoglobulines dépourvus de chaînes légères
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
WO2001019866A1 (fr) 1999-09-10 2001-03-22 The University Of Sydney Dipeptidyl peptidases
EP1268550A2 (fr) 2000-03-17 2003-01-02 Boehringer Ingelheim Pharma KG Anticorps humains specifiques de fap-alpha
GB0027552D0 (en) 2000-11-10 2000-12-27 Boehringer Ingelheim Pharma Anti-tumor compounds
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
AU2006246719A1 (en) 2005-05-19 2006-11-23 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
AU2006264305B2 (en) 2005-07-05 2012-07-05 Trustees Of Tufts College Inhibitors of fibroblast activation protein alpha
EP1760076A1 (fr) 2005-09-02 2007-03-07 Ferring B.V. Inhibiteur de FAP
EP1806365A1 (fr) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Anticorps spécifiques pour la protéine alpha d'activation de fibroblastes et leurs immunoconjugués
EP2262837A4 (fr) 2008-03-12 2011-04-06 Merck Sharp & Dohme Protéines de liaison avec pd-1
EP2328920A2 (fr) 2008-08-25 2011-06-08 Amplimmune, Inc. Polypeptides co-stimulateurs ciblés et leurs procédés d'utilisation dans le traitement du cancer
RS54233B1 (sr) 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
BRPI0919818A2 (pt) 2008-09-25 2019-09-24 Molecular Insight Pharm Inc inibidores de seprase seletivos
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
US20120053222A1 (en) 2009-01-23 2012-03-01 Mark Gorrell Novel Metabolic Disease Therapy
US8345509B2 (en) 2009-04-16 2013-01-01 Chevron U.S.A., Inc. System and method to create three-dimensional images of non-linear acoustic properties in a region remote from a borehole
CA2773515C (fr) 2009-09-29 2015-04-28 Roche Glycart Ag Anticorps agonistes bispecifiques du recepteur de mort
JP2013506664A (ja) 2009-10-02 2013-02-28 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ リミテッド 抗線維芽細胞活性化タンパク質抗体並びにその方法及び使用
EP2504028A4 (fr) 2009-11-24 2014-04-09 Amplimmune Inc Inhibition simultanée de pd-l1/pd-l2
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
SG187746A1 (en) 2010-08-13 2013-03-28 Roche Glycart Ag Anti-fap antibodies and methods of use
US20120213781A1 (en) 2011-02-11 2012-08-23 Zyngenia, Inc. Monovalent and Multivalent Multispecific Complexes and Uses Thereof
JP6207509B2 (ja) 2011-08-30 2017-10-04 トラスティーズ オブ タフツ カレッジ 固形腫瘍を治療するためのfap活性化プロテアソーム阻害剤
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-pd-l1 항체 및 그의 용도
EP2804859B1 (fr) 2012-01-17 2019-06-12 Universiteit Antwerpen Nouveaux inhibiteurs de fap
AR092745A1 (es) 2012-10-01 2015-04-29 Univ Pennsylvania Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer
US9593148B2 (en) 2012-11-02 2017-03-14 Georg-August-Universitat Gottingen Stiftung Offentlichen Rechts DPP8 and DPP9 peptide inhibitors
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
HRP20181251T1 (hr) 2013-09-06 2018-10-05 Aurigene Discovery Technologies Limited Derivati 1,3,4-oksadiazola i 1,3,4-tiadiazola kao imunomodulatori
CU24362B1 (es) 2013-09-06 2018-10-04 Aurigene Discovery Tech Ltd Derivados de 1,2,4-oxadiazol como inmunomoduladores
CN116059219A (zh) * 2015-07-16 2023-05-05 比奥克斯塞尔医疗股份有限公司 一种使用免疫调节治疗癌症的新颖方法
US11613785B2 (en) 2017-01-09 2023-03-28 Onkosxcel Therapeutics, Llc Predictive and diagnostic methods for prostate cancer

Also Published As

Publication number Publication date
EP3565560A1 (fr) 2019-11-13
EP3565560B1 (fr) 2024-05-29
US20210355541A1 (en) 2021-11-18
WO2018129497A1 (fr) 2018-07-12
US20230227918A1 (en) 2023-07-20
ES2988845T3 (es) 2024-11-21
US11613785B2 (en) 2023-03-28
EP3565560A4 (fr) 2021-01-13

Similar Documents

Publication Publication Date Title
IL271888A (en) Therapeutic and diagnostic methods for cancer
EP3692164A4 (fr) Marqueurs de méthylation pour le diagnostic du cancer
IL274246A (en) Methods for diagnosing and treating cancer
IL325217A (en) Cancer treatment and diagnosis methods
IL268396A (en) Diagnostic and therapeutic methods for cancer
IL265759A (en) Therapeutic and diagnostic methods for cancer
IL261422A (en) Therapeutic and diagnostic methods for cancer
EP3565560A4 (fr) Procédés prédictifs et diagnostiques pour le cancer de la prostate
IL264674B1 (en) Antibodies to siglec7 for cancer treatment
IL255312A0 (en) Therapeutic and diagnostic methods for cancer
IL256025A (en) Methods of diagnosing and treating cancer
IL262208A (en) Diagnostic and therapeutic methods for cancer
IL270717A (en) Biomarkers for diagnosis of lung cancer
EP3403093A4 (fr) Biomarqueurs de type auto-anticorps plasmatiques pour le diagnostic du cancer du poumon
EP3490677A4 (fr) Marqueurs lipidiques, protéiques et métaboliques pour le diagnostic et le traitement du cancer de la prostate
ZA201801024B (en) 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
EP3383407A4 (fr) Conjugués de cytarabine pour le traitement du cancer
ZA202000851B (en) Antibodies useful in cancer diagnosis
EP3359696A4 (fr) Test diagnostique pour surveillance urinaire du cancer de la vessie
EP3469101A4 (fr) Procédés et compositions pour le diagnostic et le traitement du cancer de la prostate
HUE054864T2 (hu) In vitro módszer tüdõrák diagnosztizálására
EP3341079A4 (fr) Procédés et compositions pour le diagnostic et le traitement du cancer
MA40636A (fr) Procédés pour détecter le cancer de la prostate
EP3419526A4 (fr) Procédés et dispositifs pour le diagnostic des trompes de fallope
EP3839513C0 (fr) Utilisation de complexes de facteur de transcription-adn pour la détection du cancer